{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T16:03:33Z","timestamp":1791389013383,"version":"4.3.3"},"reference-count":52,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Archivos de la Sociedad Espa\u00f1ola de Oftalmolog\u00eda (English Edition)"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.oftale.2023.04.014","type":"journal-article","created":{"date-parts":[[2023,6,5]],"date-time":"2023-06-05T12:15:44Z","timestamp":1685967344000},"page":"367-376","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Differential diagnosis of endophthalmitis after intravitreal drug injection for age related macular degeneration: sterile vs. infectious"],"prefix":"10.1016","volume":"98","author":[{"given":"S.","family":"Montol\u00edo-Marzo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Vidal-Oliver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Montol\u00edo-Marzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Dolz-Marco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Gallego-Pinazo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.oftale.2023.04.014_bib0005","doi-asserted-by":"crossref","first-page":"4151","DOI":"10.1007\/s10792-021-01967-y","article-title":"Endophthalmitis: a bibliographic review","volume":"41","author":"Wade","year":"2021","journal-title":"Int Ophthalmol."},{"issue":"5","key":"10.1016\/j.oftale.2023.04.014_bib0010","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.oftal.2020.01.019","article-title":"Clinical features, management and outcomes of patients with sterile endophthalmitis associated with intravitreal injection of antivascular endothelial growth factor","volume":"95","author":"Gil-Mart\u00ednez","year":"2020","journal-title":"Arch Soc Esp Oftalmol."},{"issue":"2","key":"10.1016\/j.oftale.2023.04.014_bib0015","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.ophtha.2020.07.060","article-title":"Nonadherence or nonpersistence to intravitreal injection therapy for neovascular age-related macular degeneration: a mixed-methods systematic review","volume":"128","author":"Okada","year":"2021","journal-title":"Ophthalmology."},{"issue":"1","key":"10.1016\/j.oftale.2023.04.014_bib0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40942-021-00307-7","article-title":"Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative review","volume":"7","author":"Anderson","year":"2021","journal-title":"Int J Retin Vitr."},{"issue":"9","key":"10.1016\/j.oftale.2023.04.014_bib0025","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1097\/IAE.0000000000003556","article-title":"a Consensus on risk mitigation for brolucizumab in neovascular age-related macular degeneration","volume":"42","author":"Holz","year":"2022","journal-title":"Retina."},{"key":"10.1016\/j.oftale.2023.04.014_bib0030","doi-asserted-by":"crossref","first-page":"A7","DOI":"10.1016\/j.ajo.2020.05.012","article-title":"Is this a 737 max moment for brolucizumab?","volume":"216","author":"Rosenfeld","year":"2020","journal-title":"Am J Ophthalmol."},{"issue":"10","key":"10.1016\/j.oftale.2023.04.014_bib0035","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/j.ophtha.2020.03.035","article-title":"Efficacy and safety of abicipar in neovascular age-related macular degeneration: 52-week results of phase 3 randomized controlled study","volume":"127","author":"Kunimoto","year":"2020","journal-title":"Ophthalmology."},{"issue":"7","key":"10.1016\/j.oftale.2023.04.014_bib0040","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/j.ophtha.2020.11.017","article-title":"Two-year results of the phase 3 randomized controlled study of abicipar in neovascular age-related macular degeneration","volume":"128","author":"Khurana","year":"2021","journal-title":"Ophthalmology."},{"issue":"9","key":"10.1016\/j.oftale.2023.04.014_bib0045","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1080\/14712598.2020.1782379","article-title":"Abicipar pegol for neovascular age-related macular degeneration","volume":"20","author":"Hussain","year":"2020","journal-title":"Expert Opin Biol Ther."},{"issue":"6","key":"10.1016\/j.oftale.2023.04.014_bib0050","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1097\/IAE.0000000000002998","article-title":"Clinical outcomes and treatment course of eyes with neovascular age-related macular degeneration following the development of endophthalmitis","volume":"41","author":"Koulisis","year":"2021","journal-title":"Retina."},{"issue":"1","key":"10.1016\/j.oftale.2023.04.014_bib0055","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1177\/2474126418806832","article-title":"Distinguishing between infectious endophthalmitis and noninfectious inflammation following intravitreal anti-VEGF injection","volume":"3","author":"Schwartz","year":"2019","journal-title":"J Vitreoretin Dis."},{"key":"10.1016\/j.oftale.2023.04.014_bib0060","first-page":"773","article-title":"Global reported endophthalmitis risk following intravitreal injections of anti-VEGF: a literature review and analysis","volume":"9","author":"Sigford","year":"2015","journal-title":"Clin Ophthalmol."},{"issue":"7","key":"10.1016\/j.oftale.2023.04.014_bib0065","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1097\/IAE.0b013e3181cd47ed","article-title":"Clinical characteristics of endophthalmitis after an injection of intravitreal antivascular endothelial growth factor","volume":"30","author":"Mezad-Koursh","year":"2010","journal-title":"Retina."},{"issue":"3","key":"10.1016\/j.oftale.2023.04.014_bib0070","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1177\/24741264211028435","article-title":"Management patterns and outcomes for intravitreal injection\u2013related endophthalmitis","volume":"6","author":"Soundararajan","year":"2022","journal-title":"J Vitreoretin Dis."},{"issue":"2","key":"10.1016\/j.oftale.2023.04.014_bib0075","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.ophtha.2012.07.083","article-title":"Acute intraocular inflammation caused by endotoxin after intravitreal injection of counterfeit bevacizumab in Shanghai, China","volume":"120","author":"Wang","year":"2013","journal-title":"Ophthalmology."},{"issue":"5","key":"10.1016\/j.oftale.2023.04.014_bib0080","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10050981","article-title":"Inflammatory complications of intravitreal anti-VEGF injections","volume":"10","author":"Cox","year":"2021","journal-title":"J Clin Med."},{"issue":"5","key":"10.1016\/j.oftale.2023.04.014_bib0085","doi-asserted-by":"crossref","first-page":"313","DOI":"10.3928\/23258160-20180501-04","article-title":"Endophthalmitis associated with intravitreal injections of anti-VEGF agents at a tertiary referral center: in-house and referred cases","volume":"49","author":"Yannuzzi","year":"2018","journal-title":"Ophthalmic Surg Lasers Imaging Retina."},{"issue":"7","key":"10.1016\/j.oftale.2023.04.014_bib0090","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1016\/j.ophtha.2020.11.011","article-title":"Risk of inflammation, retinal vasculitis, and retinal occlusion-related events with brolucizumab: post hoc review of HAWK and HARRIER","volume":"128","author":"Mon\u00e9s","year":"2021","journal-title":"Ophthalmology."},{"issue":"1","key":"10.1016\/j.oftale.2023.04.014_bib0095","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ophtha.2019.04.017","article-title":"HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration","volume":"127","author":"Dugel","year":"2020","journal-title":"Ophthalmology."},{"key":"10.1016\/j.oftale.2023.04.014_bib0100","unstructured":"Dendrita Health Marketing. Bayer informa los resultados de los ensayos P-III (PULSAR) y P-II\/III (PHOTON) de Aflibercept para la degeneraci\u00f3n macular neovascular relacionada con la edad y el edema macular diab\u00e9tico [Internet]. 2022. Available from: https:\/\/dendrita.mx\/bayer-informa-los-resultados-de-los-ensayos-p-iii-pulsar-y-p-ii-iii-photon-de-aflibercept-para-la-degeneracion-macular-neovascular-relacionada-con-la-edad-y-el-edema-macular-diabetico\/."},{"issue":"9","key":"10.1016\/j.oftale.2023.04.014_bib0105","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.ophtha.2022.04.028","article-title":"MERLIN: phase 3a, multicenter, randomized, double-masked trial of brolucizumab in participants with neovascular age-related macular degeneration and persistent retinal fluid","volume":"129","author":"Khanani","year":"2022","journal-title":"Ophthalmology."},{"issue":"3","key":"10.1016\/j.oftale.2023.04.014_bib0110","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1007\/s10384-022-00908-1","article-title":"Switching from aflibercept to brolucizumab for the treatment of refractory neovascular age-related macular degeneration","volume":"66","author":"Ota","year":"2022","journal-title":"Jpn J Ophthalmol."},{"key":"10.1016\/j.oftale.2023.04.014_bib0115","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ajo.2022.01.004","article-title":"KESTREL and KITE: 52-week results from two phase III pivotal trials of brolucizumab for diabetic macular edema","volume":"238","author":"Brown","year":"2022","journal-title":"Am J Ophthalmol."},{"issue":"10326","key":"10.1016\/j.oftale.2023.04.014_bib0120","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/S0140-6736(22)00018-6","article-title":"Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials","volume":"399","author":"Wykoff","year":"2022","journal-title":"Lancet."},{"issue":"10326","key":"10.1016\/j.oftale.2023.04.014_bib0125","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/S0140-6736(22)00010-1","article-title":"Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials","volume":"399","author":"Heier","year":"2022","journal-title":"Lancet."},{"issue":"2","key":"10.1016\/j.oftale.2023.04.014_bib0130","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/s41433-022-02246-5","article-title":"Approved biosimilar ranibizumab-a global update","volume":"37","author":"Sharma","year":"2023","journal-title":"Eye (Lond)."},{"key":"10.1016\/j.oftale.2023.04.014_bib0135","unstructured":"Ximluci [Internet]. 2022. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/ximluci."},{"key":"10.1016\/j.oftale.2023.04.014_bib0140","unstructured":"Byooviz [Internet]. 2022. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/byooviz."},{"key":"10.1016\/j.oftale.2023.04.014_bib0145","unstructured":"Ranivisio. 2022."},{"issue":"2","key":"10.1016\/j.oftale.2023.04.014_bib0150","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1001\/jamaophthalmol.2022.5403","article-title":"Immunogenicity with ranibizumab biosimilar SB11 (Byooviz) and reference product lucentis and association with efficacy, safety, and pharmacokinetics: a post hoc analysis of a phase 3 randomized clinical trial","volume":"141","author":"Bressler","year":"2023","journal-title":"JAMA Ophthalmol."},{"issue":"5","key":"10.1016\/j.oftale.2023.04.014_bib0155","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1177\/11206721211059332","article-title":"Ocular adverse events following intravitreal brolucizumab for neovascular age-related macular degeneration at a single tertiary care center","volume":"32","author":"Nguyen","year":"2022","journal-title":"Eur J Ophthalmol."},{"issue":"4","key":"10.1016\/j.oftale.2023.04.014_bib0160","doi-asserted-by":"crossref","first-page":"468","DOI":"10.4103\/0301-4738.111192","article-title":"Batch-related sterile endophthalmitis following intravitreal injection of bevacizumab","volume":"62","author":"Entezari","year":"2014","journal-title":"Indian J Ophthalmol."},{"issue":"5","key":"10.1016\/j.oftale.2023.04.014_bib0165","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/j.ophtha.2012.11.018","article-title":"Aflibercept-related sterile inflammation","volume":"120","author":"Hahn","year":"2013","journal-title":"Ophthalmology."},{"key":"10.1016\/j.oftale.2023.04.014_bib0170","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1001\/jamaophthalmol.2014.5650","article-title":"Postmarketing analysis of aflibercept-related sterile intraocular inflammation","volume":"133","author":"Hahn","year":"2015","journal-title":"JAMA Ophthalmol."},{"issue":"4","key":"10.1016\/j.oftale.2023.04.014_bib0175","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1177\/2474126420930863","article-title":"Occlusive retinal vasculitis following intravitreal brolucizumab","volume":"4","author":"Witkin","year":"2020","journal-title":"J Vitreoretin Dis."},{"issue":"9","key":"10.1016\/j.oftale.2023.04.014_bib0180","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1097\/IAE.0b013e3181dc04da","article-title":"Characterization of sterile intraocular inflammatory responses after intravitreal bevacizumab injection","volume":"30","author":"Chong","year":"2010","journal-title":"Retina."},{"issue":"4","key":"10.1016\/j.oftale.2023.04.014_bib0185","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1007\/s00417-021-05454-z","article-title":"Differences in the incidence of aflibercept-related sterile endophthalmitis according to types of disposable syringes used","volume":"260","author":"Kim","year":"2022","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"0","key":"10.1016\/j.oftale.2023.04.014_bib0190","article-title":"Clinical practice update: management of infectious endophthalmitis after intravitreal anti-VEGF injection","volume":"0","author":"Merani","year":"2022","journal-title":"J Vitreoretin Dis"},{"issue":"7","key":"10.1016\/j.oftale.2023.04.014_bib0195","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/eye.2013.107","article-title":"Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature","volume":"27","author":"Falavarjani","year":"2013","journal-title":"Eye (Lond)"},{"issue":"3","key":"10.1016\/j.oftale.2023.04.014_bib0200","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.oftal.2016.09.006","article-title":"Endophthalmitis after intravitreal injections. Incidence, management and prognosis","volume":"92","author":"Tarrag\u00f3","year":"2017","journal-title":"Arch Soc Esp Oftalmol."},{"issue":"10","key":"10.1016\/j.oftale.2023.04.014_bib0205","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1016\/j.ophtha.2011.02.034","article-title":"Outcomes and risk factors associated with endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents","volume":"118","author":"Shah","year":"2011","journal-title":"Ophthalmology."},{"issue":"1","key":"10.1016\/j.oftale.2023.04.014_bib0210","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s12348-015-0069-5","article-title":"Endophthalmitis following intravitreal injection of anti-VEGF agents: long-term outcomes and the identification of unusual micro-organisms","volume":"6","author":"Sachdeva","year":"2016","journal-title":"J Ophthalmic Inflamm Infect."},{"issue":"4","key":"10.1016\/j.oftale.2023.04.014_bib0215","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1097\/IAE.0b013e31821067c4","article-title":"Endophthalmitis after intravitreal vascular [corrected] endothelial growth factor antagonists: a six-year experience at a university referral center","volume":"31","author":"Moshfeghi","year":"2011","journal-title":"Retina."},{"issue":"6","key":"10.1016\/j.oftale.2023.04.014_bib0220","doi-asserted-by":"crossref","first-page":"319","DOI":"10.3928\/23258160-20210528-04","article-title":"Trends in endophthalmitis associated with intravitreal injection of anti-VEGF agentsat a tertiary referral center","volume":"52","author":"Reyes-Capo","year":"2021","journal-title":"Ophthalmic Surg Lasers Imaging Retina."},{"issue":"8","key":"10.1016\/j.oftale.2023.04.014_bib0225","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/j.ophtha.2018.01.022","article-title":"Endophthalmitis after intravitreal injection of vascular endothelial growth factor inhibitors: management and visual outcomes","volume":"125","author":"Xu","year":"2018","journal-title":"Ophthalmology."},{"key":"10.1016\/j.oftale.2023.04.014_bib0230","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ajo.2016.02.028","article-title":"Postinjection endophthalmitis rates and characteristics following intravitreal bevacizumab, ranibizumab, and aflibercept","volume":"165","author":"Rayess","year":"2016","journal-title":"Am J Ophthalmol."},{"issue":"1","key":"10.1016\/j.oftale.2023.04.014_bib0235","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1001\/jamaophthalmol.2021.4585","article-title":"Safety outcomes of brolucizumab in neovascular age-related macular degeneration: results from the IRIS registry and komodo healthcare map","volume":"140","author":"Khanani","year":"2022","journal-title":"JAMA Ophthalmol."},{"issue":"6","key":"10.1016\/j.oftale.2023.04.014_bib0240","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.oret.2020.09.020","article-title":"Expert opinion on management of intraocular inflammation, retinal vasculitis, and vascular occlusion after brolucizumab treatment","volume":"5","author":"Baumal","year":"2021","journal-title":"Ophthalmol Retin."},{"issue":"4","key":"10.1016\/j.oftale.2023.04.014_bib0245","doi-asserted-by":"crossref","first-page":"670","DOI":"10.18502\/jovr.v16i4.9757","article-title":"Side effects of brolucizumab","volume":"16","author":"Motevasseli","year":"2021","journal-title":"J Ophthalmic Vis Res."},{"key":"10.1016\/j.oftale.2023.04.014_bib0250","article-title":"Guidance on brolucizumab management recommendations","author":"Fonollosa","year":"2022","journal-title":"Arch Soc Esp Oftalmol."},{"key":"10.1016\/j.oftale.2023.04.014_bib0255","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1080\/09273948.2021.1897628","article-title":"Understanding retinal vasculitis associated with brolucizumab: complex pathophysiology or occam\u2019s razor?","volume":"30","author":"Sharma","year":"2022","journal-title":"Ocul Immunol Inflamm"},{"issue":"10","key":"10.1016\/j.oftale.2023.04.014_bib0260","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/j.ophtha.2020.04.017","article-title":"Retinal vasculitis and intraocular inflammation after intravitreal injection of brolucizumab","volume":"127","author":"Baumal","year":"2020","journal-title":"Ophthalmology."}],"container-title":["Archivos de la Sociedad Espa\u00f1ola de Oftalmolog\u00eda (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2173579423000919?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2173579423000919?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T03:29:15Z","timestamp":1761881355000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2173579423000919"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":52,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["S2173579423000919"],"URL":"https:\/\/doi.org\/10.1016\/j.oftale.2023.04.014","relation":{},"ISSN":["2173-5794"],"issn-type":[{"value":"2173-5794","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Differential diagnosis of endophthalmitis after intravitreal drug injection for age related macular degeneration: sterile vs. infectious","name":"articletitle","label":"Article Title"},{"value":"Archivos de la Sociedad Espa\u00f1ola de Oftalmolog\u00eda (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.oftale.2023.04.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.oftal.2023.04.004","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Sociedad Espa\u00f1ola de Oftalmolog\u00eda. Published by Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}